Teva's Ajovy Shows Sustained Long-Term Efficacy in Migraine Prevention Trial

Teva Pharmaceutical (NYSE:TEVA) is one of the most undervalued large cap stocks to buy according to analysts. On June 24, Teva Pharmaceutical announced the final analysis results from its PEARL Phase IV migraine prevention trial for Ajovy (fremanezumab), which is an anti-calcitonin gene-related peptide (CGRP) monoclonal antibody.

The study included individuals with both chronic and episodic migraine and confirmed the achievement of its primary and secondary endpoints. The final data demonstrated that over 66% of EM patients and 51.6% of CM patients who met the primary goal within the initial 6 months continued to experience significant benefits in migraine prevention for more than 24 months.

Furthermore, the trial observed high injection adherence rates, nearing 90%, throughout the study duration, with over 75% of subjects completing the full 24-month study. The long-term tolerability and safety profile of fremanezumab remained consistent with previous interim analyses and randomized controlled studies.

Teva Pharmaceutical (NYSE:TEVA) develops, manufactures, markets, and distributes generic and other medicines and biopharmaceutical products in the US, Europe, Israel, and internationally.

While we acknowledge the potential of TEVA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.